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Can we agree on patient-reported outcome measures for
assessing hematopoietic cell transplantation patients? A study
from the CIBMTR and BMT CTN
BE Shaw1, SJ Lee2, MM Horowitz1, WA Wood3, JD Rizzo1 and KE Flynn4
Much research into the impact of hematopoietic cell transplantation (HCT) on recipients’ symptoms, functioning and health-related
quality of life uses diverse patient-reported outcome (PRO) measures. Robust conclusions regarding PROs in HCT patients are
constrained by methodological issues, including the use of multiple different and noncomparable assessment measures. We
reviewed 114 publications addressing PROs in HCT patients. Although three multi-item measures were most frequently used
(FACT-BMT, n= 28; European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30, n= 26; and
SF-36, n= 26), 25 additional measures were used in more than one study. Another 50 measures were used in single studies. Over
50% of studies used more than one measure. We recommend that the field agrees upon a set of measures to address the core
domains important to patients, to reduce heterogeneity and allow comparisons across studies and between different populations.
Measures should be available in a free and easily accessible manner internationally. We discuss the relative benefits of the National
Institutes of Health-supported Patient-Reported Outcomes Measurement Information System (PROMIS) system to achieve these
goals. To further address these issues, the Blood and Marrow Transplant Clinical Trials Network has recently created a task force to
implement PROMIS measures alongside traditional PRO measures in future clinical trials. Robust comparisons between measures in
this setting may allow for the development of a standard for HCT patients.
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INTRODUCTION
Patient-reported outcomes (PROs) are generally understood to
encompass symptoms, functional status and perceptions of
health status or health-related quality of life (HRQoL) as reported
directly by the patient without interpretation by clinicians
(http://www.fda.gov/Drugs/DevelopmentApprovalProcess/DrugDe
velopmentToolsQualificationProgram/ucm370262.htm; accessed
on 2 July 2015). The importance of the concepts that the PROs
measure is endorsed by patients, particularly as therapies improve
and long-term survivorship increases. In addition to survival, the
American Society of Clinical Oncology recognizes the importance
of HRQoL.1 There is general agreement that using PROs to assess
HRQoL is the gold standard: accuracy and completeness are
enhanced when patients report on their health status directly,2
physicians frequently overestimate HRQoL compared with
patients’ self-reports3 and parents underestimate the HRQoL of
their children.4,5 There are collateral benefits too. At least two
clinical studies, including a randomized controlled trial, show that
the incorporation of PROs into hematopoietic cell transplantation
(HCT) follow-up care can result in better patient–physician
communication and enhance patient satisfaction.6,7
There is a large body of literature addressing the importance of
PROs to HCT patients, both in the early posttransplant and in the
longer term survivorship periods. However, there is a lack of
consensus about the best measures to use. In addition, little is
known about how physicians interpret or use PRO results from
research studies in assessing their patients and recommending
treatments.8
The aim of this study was to review the literature to summarize
the past and current landscape of multi-item PRO measures in the
assessment of health status or HRQoL in patients undergoing HCT
and to propose strategies to harmonize the measures for PRO data
collection in future research studies.
METHODS
A PubMed search was conducted on 21 October 2014 using the
following search terms: QoL and Bone Marrow Transplantation
(BMT), HRQoL and BMT, QoL and Hematopoietic Stem
Cell Transplantation and HRQoL and Hematopoietic Stem cell
transplantation. These search terms were chosen to mirror those
used by Pidala et al.9 Criteria for inclusion were: allogeneic
transplants alone or allogeneic and autologous transplants, adult
recipients and at least one quantitative multi-item PRO measure of
health status or HRQoL. Reports of autologous transplantation
alone were excluded as in the report of Pidala et al.9 and in view of
the great diversity of indications for which these transplantations
were performed. This search yielded 2171 publications. Duplicates
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(n= 574), papers prior to 2004 (n= 650) and papers not in English
(n= 56) were removed. Studies dealing with a pediatric
population (n= 59) only or autologous transplantation, including
transplantation for a solid tumor or autoimmune indication
(n= 816) only, were removed. PROs related to a specific
intervention, such as the use of an exercise program (n= 16)
were also removed, as they used measures specific to the
targeted intervention rather than addressing general outcomes.
A total of 59 studies thus fit the criteria for inclusion.
Three large reviews with similar inclusion criteria (but different
objectives) have been published9–11 and were considered in this
review. Fifty-five studies identified in those reviews, but not in the
current literature search, were added, resulting in a final number
of 114 manuscripts included in this review.
Multi-item PRO measures were identified from the methods
sections of the papers or from the relevant tables in the reviews
by Pidala et al.,9 Mosher et al.11 and Braamse et al.10 In addition,
we reviewed the multi-item PRO measures used in Blood and
Marrow Transplant Clinical Trials Network (BMT CTN) prospective
clinical trials since 2004. The BMT CTN is a National Institutes of
Health (NIH)-funded multicenter trials network addressing issues
in HCT. The study and manuscript were approved by the BMT CTN
publications committee.
RESULTS
Measures
In the 114 studies, there were 28 multi-item PRO measures used in
two or more studies involving the HCT population (Table 1). The
measures most frequently used were the FACT-BMT in 28 studies,
European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire (EORTC QLQ)-C30 in 26 studies and
the SF-36 in 26 studies. Only two other measures were used in45
studies, the Sickness Impact Profile (SIP) and the Hospital Anxiety
and Depression Scale. Of the five most commonly used measures,
one is specific for cancer patients (EORTC) and one for BMT
(FACT-BMT), whereas the others were all developed in general
patients and/or the healthy population. Twenty-five other
multi-item PRO measures were each used in 2–4 studies
(Table 1), and 450 additional measures, addressing multiple
areas of health, were used in at least one study (Table 2). Over 50%
of the studies reviewed used more than one measure for the PRO
assessment.
Domains/subscales
Table 3 shows the domains that are addressed by the most
commonly used measures. The measures are extremely diverse in
the domains that they capture. As shown, the top three have
multiple overlapping domains, although, as discussed below,
there can be poor agreement between what appear to be similar
domains. The less frequently used measures commonly address a
single domain, for example, depression (Table 2).
Respondent burden
Respondent burden is the time, effort and other demands
imposed on the respondents by the survey. The majority of
multi-item measures can be completed in a 5–10 min period
depending on the number of questions and mode and method of
administration (Table 1). Measures investigating a single domain
(for example, fatigue) or a short general overview (for example,
SF-12) can be as short as 2–3 min to complete. A few would take
significantly longer to complete (for example, SIP or CARES at
30–34 min). The time burden clearly reflects the number of
items/questions in the measure, ranging from as few as 5 to as
many as 139 questions (Table 1); however, the total time taken
when multiple different measures are used in studies is not always
reported. Almost all of the measures use an ordinal scale and are
completed by the patient directly without the need for interviews
(that is, self-administered on paper or electronically).
Access
We were also interested in assessing the ease of access for
investigators making use of these instruments and included the
results in Table 1. Payment is required for a minority of measures
(particularly for non-funded studies), however, many of the
measures require a license or permission for their use. In some
cases, the scores cannot be generated without access to
proprietary scoring algorithms.
Blood and marrow transplant clinical trials network
We reviewed the studies performed by the BMT CTN, which had a
PRO as a primary (n= 1) or secondary outcome (n= 8) (one
pediatric study excluded) in 18 trials performed since 2004. Ten
different multi-item measures were used in these studies. As in the
observational studies, the most commonly used measures were
the SF-36 (n= 6) and FACT-BMT (n= 7), with only one study using a
single instrument. In one study, PROs were the primary end point
(BMT CTN 0902) and seven separate multi-item measures were
used here.
DISCUSSION
Our study shows that many different multi-item measures are
used to assess the PROs of patients undergoing HCT. We are not
the first investigators to make this observation and call for
harmonization of practice. In fact, virtually all recent reviews
addressing PROs in HCT point out the limitations in comparing
studies due to heterogeneity in the measures used, but to date no
collaborative groups have adopted proactive strategies to address
this issue in a definitive manner.2,7,10,12
An additional problem, highlighted by Pidala et al.,9 is that
although some of the PRO measures used are specific for the HCT
population, many were designed for the general population. This
leads to the incorporation of multiple measures within a single
study to address both HCT-specific issues and also cover more
general concerns. There are potential problems with this
approach. In many cases, there is overlap of similar domains
among the measures selected resulting in increased burden for
the patients completing measures with no clear added benefit
and a potential for increased missing/incomplete data. Moreover,
assessment of similar domains by different measures may result in
conflicting interpretations.13 For example, Kopp et al.14 compared
results from the FACT-BMT and the EORTC QLQ-C30 in HCT
patients and found poor agreement between some theoretically
similar domains (for example, emotional). These are two of the
most commonly used measures and are very seldom used
together in studies, but Kopp’s study calls into question the
validity of comparisons between studies that use one or the other.
Perhaps, most importantly, the use of the large number
of different measures makes it difficult to compare the impact
of different transplantation strategies on PROs, even if the time
points measured and patient populations are similar. The impact
of the transplantation procedure on PROs is also limited by the
cross-sectional nature of many studies, with no baseline/
pretransplant assessment for comparison. Therefore, although
there is no paucity of validated measures to assess PROs after HCT,
there are barriers to using the accumulated data to calculate
general transplant ‘norms’ (to which transplant patients and their
physicians can compare themselves).
Transplantation is a relatively rare treatment within any
individual country, and international collaboration is a hallmark
of the transplantation community. Inclusion of PROs is hampered
if multi-item measures are not translated and validated in multiple
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languages besides English. With increased diversity of language
groups within individual countries, this is an issue within borders
too, especially for clinical trials or research studies that frequently
exclude non-English speaking patients because of lack of
validated instruments in all relevant languages.
To begin the process of coming to a consensus on measuring
PROs in HCT, it is important to first agree which domains should
be included in the assessments for HCT patients. Core domains
should include physical, mental and social components, with the
consideration of measuring social functioning at baseline, and a
limited set of measures to address these domains is essential. This
set of measures should be easily accessible and not too
burdensome for patients to complete. Once a standard set of
measures is agreed upon by the field, more extensive additional
measures could be endorsed for certain settings, using measures
that complement the core items without duplication. Some areas
that researchers10 have suggested may be important, but which
are not included in most multi-domain measures, are sexual
function and intimacy, cognitive functioning, social and role
functioning (for example, return to work, concern for caregivers,
relationship difficulties and post-traumatic growth). An attractive
solution may be to build new HCT-specific questionnaires (both
‘core’ and ‘extended’) from items within a single system.
In most of the reviewed studies, measures were completed by
the patients using pen and paper. Electronic methods may have
several advantages in the modern era where access to the
internet and comfort levels with communicating electronically is
widespread. The Pew report in 2014 showed that 87% of American
adults now use the internet, with near-saturation usage among
those living in households earning $75,000 or more (99%), young
adults aged 18–29 (97%) and those with college degrees (97%).
Among the White, African-American and Hispanic populations, it is
83%, 77% and 71%, respectively (http://www.pewinternet.org/
2014/02/27/part-1-how-the-internet-has-woven-itself-into-ameri
can-life/). In addition, 470% of internet users access the internet
for health information. Although this figure is generally lower in
the developing world, internet usage has increased from ~ 20% in
2010 to 32% in 2014 with no sign of a plateau (https://en.
wikipedia.org/wiki/Global_Internet_usage). This is an especially
attractive option when considering large-scale collection of PRO,
such as may occur in multicenter clinical trials or registry-based
studies, and avoids additional data entry. A critical advantage
would be the possibility of linking the PRO directly to the
Electronic Health Record (EHR), functionality that is rarely available
currently, but is anticipated to be more widespread in the future.
This could advance efforts to improve routine patient care in a
Table 1. Measures used in 114 HRQoL studies in HCT (excluding those used in only one study)
Form No. of
studies
Multidimensional vs
limited domain
Minutes to
complete
Access Target
population
Question type
FACT-BMT (TOI) 28 M 5–10 F, R HCT 47 (ordinal scale)
EORTC QLQ-C30 26 M 10 L (F in academic) Cancer 30 y/n or ordinal
scale
SF-36 26 M 5–10 L (F for academic) Healthy/patient 36 y/n or ordinal
scale
HADS (Hospital Anxiety and Depression
Scale)
7 LD 2–5 F Patient 14 (ordinal scale)
SIP (Sickness Impact Profile) 6 M 20–30 F for non-funded
studies
Patient 136 (ordinal
scale)
Study-specific/local questionnaire 5 NA NA NA NA
Chronic GvHD Symptom Scale 4 M 5 F GvHD 30 (ordinal scale)
COH (City of Hope) -QOL (BMT) 4 M 10–20 F HCT/cancer 41/84 items by
interview
FACT-G 4 M 5–10 F, R Cancer 28 (ordinal scale)
POMS (SF) (profile of mood state) 4 LD 3–7 P Psychiatry/
psychology
65 (30) (ordinal
scale)
SLDS-C (BMT) —Satisfaction with Life
Domains Scale for Cancer
4 LD o10 HCT 18 (faces)
SF-12 4 M o3 L (F for academic) Healthy/patient 12 y/n or ordinal
scale
Center for Epidemiological Studies (CES)-D
(Depression)
4 LD 5–10 F Healthy 20 (ordinal)
FACIT (-Spiritual) 3 LD 5–10 F, R Cancer/chronic
illness
12 (ordinal scale)
BDI (Beck's Depression Inventory) 3 LD 5–10 P Psychiatry/
psychology
21 (ordinal scale)
RSCL (Rotterdam Symptom Checklist) 3 M 8 F Cancer 39 (ordinal scale)
Symptom Checklist-90 (revised) 3 M 12–15 P Healthy 413 90 (ordinal scale)
Spielberger State Anxiety Scale (subscale) 3 LD 10 P Patient 40/20 (ordinal
scale)
CAncer Rehabilitation Evaluation System
(CARES-SF)
2 M 10–34 F Cancer 59/139 (ordinal
scale)
NHP (Nottingham Health Profile) 2 M 10–15 Healthy/patient 38 y/n
HRQoL index 2 M 10 R, F in academic 66 (ordinal scale)
EQ-5D (VAS) 2 LD 1–2 R, P Healthy/patient 5 (Visual analog)
SDS (Symptom Distress Scale) 2 LD 5–10 Permission granted
on request
Cancer 13 (ordinal scale)
HAP (Human Activity Profile) 2 LD 5–7 F in academic COPD 94
EORTC QLQ-HDC29 2 MD L (F in academic) Cancer 29 (ordinal scale)
(Revised) Piper Fatigue Scale 2 LD o2 F Cancer 27 (1–10, 4 open
ended)
Coping Responses Inventory 2 LD 10–15 P Healthy 48 (ordinal scale)
Interpersonal Support Evaluation List–Short
Form (ISEL-SF)
2 LD L (F in academic) Healthy 12/40/48 (ordinal
scale)
Abbreviations: F= free; GvHD=graft versus host disease; HCT=hematopoietic cell transplantation; L= requires license; LD= limited domain; M=multi-
dimensional; n= no; NA=not applicable; P=payment required; R= register; y= yes.
Harmonization of PROs in HCT
BE Shaw et al
1175
© 2016 Macmillan Publishers Limited, part of Springer Nature. Bone Marrow Transplantation (2016) 1173 – 1179
non-research setting through ‘comprehensive’ patient health
information with incorporation of health behaviors and psycho-
social issues into the medical record.15 It will be important to test
the same measures used in research in this setting, understanding
that real-time reporting, interpretation and the potential use of
‘triggers’ for clinical intervention is an added requirement. These
issues may be less specific to the measures used than to the
technology through which they are employed. In addition,
appropriate consenting of patients through the EHR, with
availability of these data to centralized research organizations,
will allow for the same tools to be informative both for
immediate clinical care as well as research analyses. The feasibility
of frequent electronic PRO collection, with ‘real-time’ physician
review, has been demonstrated in several settings,7,16,17
including HCT.18,19
The BMT CTN attempted to address the issue of harmonization of
measures in HCT with the development of a white paper in 2012
advocating for the use of similar instruments and assessment
points in all studies (https://web.emmes.com/study/bmt2/public/
SOSS/BMT%20CTN%20SOSS%20QOL%20white%20paper%20QOL.
pdf). The white Paper acknowledges that although most studies will
use a similar backbone of FACT-BMT and SF-36, it is often necessary
to add additional measures in individual studies to adequately
capture all aspects of PROs of interest to the study investigators and
of relevance to the intervention being tested. The white paper also
recommends that, in general, free or academically discounted
instruments should be favored. More recently, this group made a
specific recommendation for the inclusion of the NIH patients
repeated outcomes measurement information systems (PROMIS)
measures into BMT CTN studies. Development of a task force to
implement this recommendation is underway.
PROMIS captures patient-reported health status using a set of
highly reliable, valid, flexible, precise and responsive assessment
tools.20 PROMIS consists of item banks with a variable number
of questions that can be combined to form multi-item measures of
varying length and complexity. Because each item is mapped onto
a common metric, measures of differing length can be compared
with each other.13 Fixed-length multidimensional measures are
available, including profiles with 29, 43 or 57 questions. There is
also a Global Health Questionnaire of just 10 questions. Forms and
item banks are available for adults, children and parent-proxy
reporting. A more recent benefit is the incorporation of PROMIS
into Epic, an EHR widely available in US, allowing patients to
access and complete the measures directly through MyChart (Epic
Systems Corporation, Verona, WI, USA), with the results being
made available to their health-care providers.21 This functionality
is not currently operational at all Epic-using centers. Addressing
another area of need, PROMIS has an international working group
translating the measures into multiple languages, several of which
are already completed, including Spanish.
A current disadvantage to this system is that it does not contain
many items that are more specifically HCT-related, for example,
those associated with graft versus host disease (GvHD), ongoing
immunosuppression, recurrent infections and specific late
effects such as treatment-related malignancies. In addition, few
studies in HCT to date have utilized PROMIS measures. If PROMIS is
to meet the needs of the HCT community, these issues must be
addressed.
RECOMMENDATIONS
Use the same core measures in all research studies of HCT patients
The benefit of this approach is obvious as it promotes aggregation
of data and comparison among studies. It also allows investigators
to explore better any differences or similarities among different
study populations. It could potentially allow development of a
transplant patient ‘norm’ to which patients could be compared.
Ideally, a single tool taking o10 min to complete and translated
into several languages would be beneficial.
Table 2. Additional measures used in at least one study by symptom type
Symptom Instrument name
General SEIQOL, SEIQOL-DW, QLI, Health Perception Scale, KPS, ECOG PS, DSM-IV, MDASI-BMT, FLIC, Swedish
Health-Related Quality of Life Profile (SWED-QUAL), Symptom Frequency, Intensity and Distress
questionnaire for SCT (SFID-SCT)
Eyes Visual Function Questionnaire-25 (VFQ-25), Ocular Surface Disease Index (OSDI)
Symptoms Brief Symptom Inventory, Brief Symptom Inventory-18, FACT-AN (anemia), Edmonton Symptom
Assessment Scale, Brief Pain Inventory
Fatigue PROMIS fatigue 6-item, Fatigue Symptom Inventory, FQ
Nutrition Patient-Generated Subjective Global Assessment (PG-SGA)
Mental health/function FACT-Cog (cognition), PROMIS cognitive scales 8-item, neuropsychological test battery, Post-Traumatic
Stress Diagnostic scale, Post-Traumatic Stress Disorder Checklist) -civilian (PCL-C), The Fear of Progression
Questionnaire-Short Form (FoP-Q-SF), Patient Health Questionnaire (PHQ-9 ) – Depression,
Neurobehavioral Rating scale (NBRS), Modified Memory Questionnaire (MMQ)
Delirium Delirium Rating Scale, Memorial Delirium Assessment Scale
Coping Coping Inventory SF, (brief ) COPE
Sleep Medical Outcomes Study Sleep Scale
Disease-specific EORTC QLQ-LEU (Leukemia)/EORTC QLQ-LEU-BMT (Leukemia-Bone Marrow Transplant)
Sexuality Psychosexual Functioning Questionnaire (PSFQ)
Distress Cancer and Treatment Distress scale, Cancer Treatment Distress Scale, Psychosocial Adjustment to Illness
Scale (PAIS), NCCN Distress Thermometer and Problem List
Social support/adjustment/
relationships
Social Support Questionnaire, Social Support Inventory, Medical Outcomes Study Social Support Survey
(MOS-SSS), Dyadic Adjustment Scale
Satisfaction/meaningfulness Life satisfaction FLZ (Questions on Life Satisfaction), Orientation to Life Questionnaire
Medication Morisky’s Medication Compliance Scale
Miscellaneous Psychosocial Discomfort Scale (PsDS), DLQI (skin), self reported work status
Abbreviations: DSM=Diagnostic and Statistical Manual of Mental Disorders; EORTC QLQ= European Organization for Research and Treatment of Cancer
Quality of Life Questionnaire; FLIC= Functional Living Index–Cancer; KPS=Karnofsky Performance status; MDASI-BMT=MD Anderson Symptom Inventory-
Bone Marrow Transplant; NCCN=National Comprehensive Cancer Network; PROMIS= Patient-Reported Outcomes Measurement Information System;
QLI=Quality of Life Index; SEIQoL-DW= Schedule for Evaluation of Individual Quality of Life (SEIQoL)–Direct Weighting.
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Table 3. Subscales/domains in commonly used measures for hematopoietic cell transplantation studies
Form Domains/subscales
Symptom Functioning Global
health
Composite
scores/
dimensions
Other
Fatigue/
vitality
Pain Nausea Anxiety Depression Sleep Sexual Physical Social Role Cognitive Emotional ADL Mental/
psychological
FACT-BMT (TOI) x x x x x x x x x x x BMT
subscale,
Trial
Outcome
Index
EORTC QLQ-C30 x x x x x x x x x
SF-36 x x x x x x x x Physical,
mental
HADS x x
SIP (Sickness
Impact Profile)
x x x x x Physical,
psychosocial
Nutrition,
movement of the
body,
communication
activity, personal
hygiene
cGvHD
Symptom Scale
x x x x x Skin, nutrition, lung,
eye, mouth
COH-QOL (BMT) x Health status and
treatment-related
physical symptoms,
qualitative aspects
of daily life
FACT-G x x x Relationship with
doctor
POMS (SF) x x x Anger and
confusion
SLDS-C (BMT)—
Satisfaction with
Life Domains
Scale for Cancer
x x x Health, spouse,
other relatives,
friends, body,
appearance,
strength, overall
comfort, BMT,
eating, control,
quality of life, future
and life as a whole
SF-12 Physical,
mental
Center for
Epidemiological
Studies (CES)-D
(Depression)
x
FACIT (-Spiritual) x x x Spiritual well-being
BDI (Beck's
Depression
Inventory)
x Affective and
somatic subscales
RSCL
(Rotterdam
Symptom
Checklist)
x x Physical symptom
distress
Symptom
Checklist -90
(Revised)
x x Somatization,
obsessive-
compulsive,
interpersonal
sensitivity, hostility,
phobic anxiety,
paranoid ideation,
psychoticism
Spielberger
State Anxiety
Scale (subscale)
x
CAncer
Rehabilitation
Evaluation
System
(CARES-SF) x x Psychosocial,
marital, medical
interaction
NHP x x x x x x
QoL Index x Health and
functioning,
psychological/
spiritual domain,
economic domain,
and family
EQ-5D (VAS) x x x x Mobility
SDS (Symptom
Distress Scale)
x x x x Appetite, bowel,
concentration
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Use a system which is free and easy to access
To achieve international compliance with a single system of PRO
tools in HCT, these should be free and easily accessible, including
on mobile devices. A system which interacts directly with the
electronic medical record is very desirable.
Ensure a low burden for the patient
Ideally a brief measure that does not sacrifice precision, but covers
many common domains could be included for all patients.
Use a single system of items which is versatile
Where a common brief measure is insufficient to study all aspects
of interest, additional pre-existing validated items could be added.
This would remove the issue of overlap when multiple measures
from different systems are used and may allow a multi-item
measure, tailored to the HCT population, to be developed.
CONCLUSION
Developing a HRQoL focused task force within the BMT CTN
provides an opportunity for the consistent implementation of the
above recommendations in the majority of HCT patients entering
a clinical trial in US. In the short term, the use of PROMIS measures
in BMT CTN studies alongside instruments with a longer track
record (specifically, the SF-36 and FACT-BMT) would serve to
validate the measures in this population, although taking
advantage of the ongoing NIH-supported efforts of electronic
data capture and translation, using a system that is freely
available. Post hoc comparative analyses between these measures
within individual studies as well as in a cross-sectional manner
across studies may result in robust conclusions, which we hope
will promote adoption of the most discriminating common
measures by the community in general. Decisions on which
measures to use in studies addressing specific areas/domains
of PROs (for example, GvHD) should be based on the goal of
preserving the ability of each study to meet its PRO-specific aims
while ensuring the comparability and usefulness of PRO data
collection beyond the needs of a single study.
CONFLICT OF INTEREST
The authors declare no conflict of interest.
ACKNOWLEDGEMENTS
Support for this study was provided by a grant to the BMT CTN: #U10HL069294 from
the National Heart, Lung and Blood Institute and the National Cancer Institute,
and the Health Resources and Services Administration Contract No.
HHSH234200637020C. Dr Flynn was funded in part by the Research and Education
Program Fund, a component of the Advancing a Healthier Wisconsin endowment at
the Medical College of Wisconsin. Any views, opinions, findings, conclusions or
recommendations expressed in this material are those of the author(s) and do not
reflect the views or the official policy or position of the above mentioned parties.
REFERENCES
1 Outcomes of cancer treatment for technology assessment and cancer
treatment guidelines. American Society of Clinical Oncology. J Clin Oncol 1996; 14:
671–679.
2 Bevans M, Wiener L. Health-Related Quality of Life in Adult and Pediatric Survivors
of Hematopoietic Stem Cell Transplantation. In: Savani BN (ed.). Blood and Marrow
Transplantation Long-Term Management: Prevention and Complications. Wiley
Blackwell: Chichester, UK: 2013; 345–367.
3 Hendriks MG, Schouten HC. Quality of life after stem cell transplantation: a
patient, partner and physician perspective. Eur J Intern Med 2002; 13: 52–56.
4 Baca CB, Vickrey BG, Hays RD, Vassar SD, Berg AT. Differences in child versus
parent reports of the child's health-related quality of life in children with epilepsy
and healthy siblings. Value Health 2010; 13: 778–786.
5 Russell KM, Hudson M, Long A, Phipps S. Assessment of health-related quality of
life in children with cancer: consistency and agreement between parent and child
reports. Cancer 2006; 106: 2267–2274.
6 Detmar SB, Muller MJ, Schornagel JH, Wever LD, Aaronson NK. Health-related
quality-of-life assessments and patient-physician communication: a randomized
controlled trial. JAMA 2002; 288: 3027–3034.
Table 3. (Continued )
Form Domains/subscales
Symptom Functioning Global
health
Composite
scores/
dimensions
Other
Fatigue/
vitality
Pain Nausea Anxiety Depression Sleep Sexual Physical Social Role Cognitive Emotional ADL Mental/
psychological
HAP (Human
Activity Profile)
x Dyspnea
EORTC QLQ-
HDC29
x x Gastrointestinal side
effects, body image,
impact on family,
issues during
hospital stay,
physical side effects,
ability to finish
things, taking
regular drugs,
fertility, spirituality
(Revised) Piper
Fatigue Scale
x
Coping
Responses
Inventory
Approach coping
styles and avoidant
coping styles
Interpersonal
Support
Evaluation
List–Short Form
(ISEL-SF)
Appraisal support,
tangible assets
support belonging
support, self-esteem
Abbreviation: BMT=bone marrow transplantation; GvHD=graft versus host disease.
Harmonization of PROs in HCT
BE Shaw et al
1178
Bone Marrow Transplantation (2016) 1173 – 1179 © 2016 Macmillan Publishers Limited, part of Springer Nature.
7 Pidala J, Anasetti C, Jim H. Health-related quality of life following haematopoietic
cell transplantation: patient education, evaluation and intervention. Br J Haematol
2009; 148: 373–385.
8 Lee SJ, Joffe S, Kim HT, Socie G, Gilman AL, Wingard JR et al. Physicians' attitudes
about quality-of-life issues in hematopoietic stem cell transplantation. Blood 2004;
104: 2194–2200.
9 Pidala J, Anasetti C, Jim H. Quality of life after allogeneic hematopoietic cell
transplantation. Blood 2009; 114: 7–19.
10 Braamse AM, Gerrits MM, van Meijel B, Visser O, Boenink AD, Cuijpers P et al.
Predictors of health-related quality of life in patients treated with auto- and allo-
SCT for hematological malignancies. Bone Marrow Transplant 2012; 47: 757–769.
11 Mosher CE, Redd WH, Rini CM, Burkhalter JE, DuHamel KN. Physical, psychological,
and social sequelae following hematopoietic stem cell transplantation: a review of
the literature. Psychooncology 2009; 18: 113–127.
12 Norkin M, Hsu JW, Wingard JR. Quality of life, social challenges, and psychosocial
support for long-term survivors after allogeneic hematopoietic stem-cell
transplantation. Semin Hematol 2012; 49: 104–109.
13 Garcia SF, Cella D, Clauser SB, Flynn KE, Lad T, Lai JS et al. Standardizing
patient-reported outcomes assessment in cancer clinical trials: a patient-reported
outcomes measurement information system initiative. J Clin Oncol 2007; 25:
5106–5112.
14 Kopp M, Schweigkofler H, Holzner B, Nachbaur D, Niederwieser D, Fleischhacker
WW et al. EORTC QLQ-C30 and FACT-BMT for the measurement of quality of life in
bone marrow transplant recipients: a comparison. Eur J Haematol 2000; 65:
97–103.
15 Estabrooks PA, Boyle M, Emmons KM, Glasgow RE, Hesse BW, Kaplan RM et al.
Harmonized patient-reported data elements in the electronic health
record: supporting meaningful use by primary care action on health
behaviors and key psychosocial factors. J Am Med Inform Assoc 2012; 19:
575–582.
16 Bell DS, Kahn CE Jr. Health status assessment via the World Wide Web. Proc AMIA
Annu Fall Symp 1996, 338–342.
17 Suh SY, Leblanc TW, Shelby RA, Samsa GP, Abernethy AP. Longitudinal patient-
reported performance status assessment in the cancer clinic is feasible and
prognostic. J Oncol Pract 2011; 7: 374–381.
18 Bush N, Donaldson G, Moinpour C, Haberman M, Mikkiken D, Markle V et al.
Development, feasibility and compliance of a web-based system for very frequent
QOL and symptom home self-assessment after hematopoietic stem cell trans-
plantation. Qual Life Res 2005; 14: 77–93.
19 Wood WA, Deal AM, Abernethy A, Basch E, Battaglini C, Kim YH et al. Feasibility of
frequent patient-reported outcome surveillance in patients undergoing
hematopoietic cell transplantation. Biol Blood Marrow Transplant 2013; 19:
450–459.
20 Cella D, Yount S, Rothrock N, Gershon R, Cook K, Reeve B et al. The Patient-
Reported Outcomes Measurement Information System (PROMIS): progress of an
NIH roadmap cooperative group during its first two years. Med Care 2007; 45:
S3–S11.
21 Wagner LI, Schink J, Bass M, Patel S, Diaz MV, Rothrock N et al. Bringing PROMIS to
practice: brief and precise symptom screening in ambulatory cancer care. Cancer
2015; 121: 927–934.
Harmonization of PROs in HCT
BE Shaw et al
1179
© 2016 Macmillan Publishers Limited, part of Springer Nature. Bone Marrow Transplantation (2016) 1173 – 1179
